NCT04603976

Registry for Migraine - Clinical Core

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Danish Headache Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.

Detailed description

Migraine is a prevalent neurological disorder and a leading cause of years lived with disability worldwide. As of recent, therapies targeting calcitonin gene-related peptide (e.g. erenumab) have been approved for the preventive treatment of migraine. This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Erenumab	Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)

Timeline

• Start date: 2020-09-25
• Primary completion: 2022-10-01
• Completion: 2022-10-01
• First posted: 2020-10-27
• Last updated: 2020-10-27

Locations

1 site across 1 country: Denmark